In early 2021, former L'Oreal executives Michel Brousset and Hind Sebti launched a SPAC called Waldencast on the idea that beauty's future belonged to a multibrand conglomerate. By November of that year, the pitch had become a 1.2 billion dollar merger combining Obagi Medical, a physician dispensed skincare brand, with the cult cosmetics label Milk Makeup. Four years later, the empire they built has come apart, and the people now trying to fix Milk Makeup are the same cofounders that deal once pushed to the side.
How the empire was built, and who actually ran it
Brousset, formerly president of L'Oreal's Consumer Products Division, and cofounder Hind Sebti launched Waldencast Acquisition Corp in early 2021. The SPAC's defining move was the 1.2 billion dollar merger announced that November, which closed in July 2022. Brousset and Sebti both eventually departed to run Obagi alongside private equity firm Bridgepoint, taking CFO Manuel Manfredi with them, while Felipe Dutra stepped in as Waldencast's principal executive and financial officer.
The numbers behind the collapse
Milk Makeup's net revenue fell 57.1 percent to 26.1 million dollars in the first half of 2026, down from 60.9 million dollars a year earlier. Adjusted EBITDA swung from a 9.7 million dollar profit to a 14.8 million dollar loss. Waldencast took a 52.3 million dollar goodwill impairment charge on Milk alone, and the brand's implied fair value is now estimated around 180 million dollars, down sharply from a 382 million dollar enterprise value when the deal closed in 2021. Obagi, the other half of the original merger, sold to Bridgepoint for up to 460 million dollars, down from an original valuation of 858 million dollars.
What Waldencast itself says went wrong
The company cited four specific causes for the decline, distribution that expanded faster than its marketing and field education capabilities could support, 2025 product launches that failed to bring in enough new customers, a previous generation of its Sticks product line that underperformed against customer expectations on quality and value, and the absence of any launches during early summer 2026, missing the category's peak selling season entirely. Read together, that is not a demand problem, it is a brand and execution problem, distribution scaled without the marketing muscle needed to support it.




